Biocom California’s 13th Annual Global Life Science Partnering & Investor Conference is an exclusive global partnering and networking forum that brings together senior executives, bankers, venture capitalists, and business development professionals from leading pharmaceutical and biotech companies. The meeting will be held in San Diego, on February 28th to March 2nd, 2023, where industry leaders will debate current trends, companies will showcase their latest technologies and all attendees will have the opportunity to schedule one-on-one meetings with leading deal-makers.
North X Biologics is participating this conference. Come and book a meeting with us at contact@nxbio.com.
More details about this conference please click here.
The world’s leading expo in the life sciences BIO-Europe will host its first in-person edition since 2019 in Leipziger Messe on 24 – 26 October. BIO Europe Leipzig
The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies.
The Board of NorthX Biologics (“NorthX”) has appointed Helena Strigård as the new CEO. She joins NorthX from her role as Director General for the Swedish life science industry organization, SwedenBIO. Helena will lead NorthX’s continued expansion in the development and production of advanced biologics. Ted Fjällman, current CEO of NorthX and Partner of the Company’s main investor, Flerie Invest, will continue to support the company as a member of the Board.
NorthX has one of Northern Europe’s largest manufacturing capacities for clinical material in the forms of plasmid DNA, recombinant proteins, cell banking, and related gene therapy services. Since the takeover in October 2021, NorthX has recruited a Leadership Team, Sales Team and Board for the rapidly growing company. In addition to the GMP-certified production facility in Matfors, the Company is now establishing itself on the Karolinska University Hospital’s campus in Stockholm and is developing an innovation hub for ATMPs and advanced therapeutics in collaboration with Vinnova, the Swedish Innovation Agency.
NorthX is establishing itself as a partner of choice in the Nordics for cell and gene therapy companies that need GMP manufacturing services. Now the company wants to shift gears to become a global player with a continued strong focus on individual projects and customers, in a spirit of partnership according to the motto “Journey together”. During the first year, Ted Fjällman has had the role of interim CEO and during this time has successfully transitioned NorthX into a Company with all the necessary functions to develop internationally. With that foundation, the Company has now appointed a new CEO, Helena Strigård to continue the Company’s growth. Helena has broad experience from the Ministry of Finance and Vinnova and has taken the organization SwedenBIO through a period of rapid expansion, which saw the membership income doubled.
“NorthX has in a short time built up a broad capacity for advanced biologics. I am excited to be joining at this stage in the Company’s growth and will use all my industry know-how and global network to ensure that we succeed,” said Helena Strigård.
“Under Helena’s leadership, SwedenBIO has taken its place on international arenas to the benefit of the entire industry. NorthX will be able to leverage that driving force to achieve international impact. As a Board we look forward to working with her in order to achieve this important goal. I would like to take this opportunity to thank Ted Fjällman for his successful efforts as interim CEO; he has laid an important foundation for continued success for NorthX and I am grateful that he continues to serve on the Company’s Board”, added Thomas Eldered, chairman of the board of NorthX.
What: Seminar Where: Klara Strand, Klarabergsviadukten 90, Stockholm When: 19th October
We are organizing a seminar on “Drug development of Today and the Future” in collaboration with Abera Biosciences AB, Testa Center, RISE Research Institutes of Sweden, STUNS Life science and Business Sweden on the 19th of October 2022.
We are using this opportunity to invite you to participate to this event.
Be present to hear our own Eva-karin Gidlund and other eminent speakers engaged in the development of drugs talking about opportunities, problems and practical examples of the field where innovative ways of collaboration and new acquired skills were essential to surmount hurdles associated with our branch’s new demands.
The future is coming in fast, with it new challenges arise for all of us who are active in our industry. This seminar is intendent to be a platform for networking, exchange of ideas, best practices and possible solutions.
We eagerly await your participation in the seminar!
Preliminary program:
15:00 – Introduction 15:05 – Jesper Hedberg (Testa Center) 15:15 – Matti Sällberg (pre – GMP facillity) 15:25 – Eva-karin Gidlund (NorthX Biologics) 15:35 – Anna Ridderstad Wollberg (RISE) 15:45 – Coffee break 16:00 – Maria Alriksson (Abera Biosciences) 16:15 – Angelica Loskog (Lokon Pharma) 16:30 – Charlotte af Klercker & Britta Stenson (Business Sweden, followed by Q&A and discussions) 17:00 -19:00 – Mingle with snacks
“The international partnering meeting (with pre-bookable with face-to-face-meetings) The Future of Swedish and Danish Life Science will be held at Medicon Village in Lund September 7th. The meeting will be covered by the media.”
